Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01941095
- Locations
- ๐ฌ๐ท
Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens, Athens, Greece
๐ฌ๐ทUni Hospital of Ioannina; Rheumatology, Ioannina, Greece
๐ฌ๐ทGeneral Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine, Thessaloniki, Greece
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 240
- Registration Number
- NCT01940497
- Locations
- ๐ฎ๐น
Ospedale S.G.Calibita Fatebenefratelli; Unitร Operativa Oncologia, Roma, Lazio, Italy
๐ฎ๐นCampus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, Italy
๐ฎ๐นOspedale San Carlo; Day Hospital Oncologia Medica, Potenza, Basilicata, Italy
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis
- Conditions
- Anemia
- Interventions
- Drug: Methoxy polyethylene glycol epoetin beta
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT01940484
- Locations
- ๐ฟ๐ฆ
Donald Gordon Medical Centre, Johannesburg, South Africa
๐ฟ๐ฆUniversitas Private Hospital, Bloemfontein, South Africa
๐ฟ๐ฆGlynnwood Hospital, Benoni, South Africa
A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01940510
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- Conditions
- Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
- Interventions
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01932125
- Locations
- ๐ฎ๐ณ
Rajiv Gandhi Cancer Inst.&Research Center, New Delhi, Delhi, India
๐ฎ๐ณManipal Hospital, Bangalore, Karnataka, India
๐ฎ๐ณHealthCare Global Enterprises Limited, Banglore, Karnataka, India
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01928615
A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT01926886
- Locations
- ๐ฎ๐ฑ
Soroka Medical Center; Oncology Dept, Beer Sheva, Israel
๐ฎ๐ฑRabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel
๐ง๐ชAZ Maria Middelares, Gent, Belgium
A Screening Study To Assess The Cognition Status in Healthy Volunteers
- Conditions
- Healthy Volunteer
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 240
- Registration Number
- NCT01926873
A PET Study With RO5545965 in Healthy Male Volunteers
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01923025
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 806
- Registration Number
- NCT01922037
- Locations
- ๐บ๐ธ
University of Rochester, Rochester, New York, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
๐บ๐ธChest Medicine Consultants, Chicago, Illinois, United States